NCT04992247WITHDRAWNanonymous

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

PHASE2

Modality

AI-normalized

protein therapy

Target

AI-normalized

COVI-MSC, Placebo

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVI-MSC, Placebo

Related intelligence directories

Indication directory: Covid19 Modality directory: protein therapy Target directory: COVI-MSC

Source & freshness

Source record

NCT ID

NCT04992247

Original source

ClinicalTrials.gov

Source last updated

Apr 17, 2024

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04992247

Title

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Sponsor

Sorrento Therapeutics, Inc.

Status

WITHDRAWN

Phase

PHASE2

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

COVI-MSC, Placebo

Target normalized

COVI-MSC, Placebo

Interventions

COVI-MSC, Placebo

Public preview

Source record

This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT04992247

Status

WITHDRAWN

Phase

PHASE2

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 17, 2024

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04992247

Indication

Covid19

Modality

protein therapy

Target

COVI-MSC, Placebo

Intervention

COVI-MSC, Placebo

Source record